EUCTR2009-013787-39-IT进行中（未招募）不适用
A Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed in Patients with Advanced or Metastatic Non-small Cell Lung Cancer - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histological or cytological diagnosis of advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) which has progressed after first line treatment with a platinum doublet chemotherapy regimen not containing pemetrexed. Previous treatment with biological agents is permitted. [2] Patients must agree to (and be clinically able to undergo) a biopsy of the primary tumor or an accessible metastasis during the baseline Visit (Visit 0). [3] Have at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 definitions. At least 1 measurable lesion must be outside the field of any allowed prior radiotherapy; see Exclusion Criterion [11]. [4] Have a performance status of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale. [5] Males or females at least 18 years of age. Have adequate organ function including: Hematologic: Absolute neutrophil count (ANC) ≥1.5 x 109/L, platelets ≥100 x 109/L, and hemoglobin ≥9 g/dL. Transfusions are allowed to meet this requirement.Hepatic: Bilirubin ≤1.5 times upper limits of normal (ULN), aspartate transaminase (AST) <2.5 times ULN, alanine transaminase (ALT) ≤2.5 times ULN. If the liver has tumor involvement, aspartate transaminase (AST) <5 times ULN and ALT equaling ≤5 times ULN are acceptable. Patients may have endoscopic or radiologic stenting to treat biliary obstructions. If so, then bilirubin must return to <1.5 times ULN, alkaline phosphatase (AP) and aspartate transaminase (AST) to <5 times ULN, and ALT to ≤5 times ULN prior to enrollment. Renal: Calculated creatinine clearance (Cockroft-Gault formula; see Protocol Attachment JMMD.4), greater than or equal to 45 mL/min.Prior radiation therapy for treatment of cancer is allowed to <25% of the bone marrow (Christy and Eckerman 1987) and patients must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study entry. At least 1 measurable lesion must be outside the previous radiotherapy field.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Are currently enrolled in, or discontinued within the last 28 days from, a clinical trial involving the use of an investigational drug or device (other than the study drug used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. [14] Have serious preexisting medical conditions or serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator (for example, unstable angina pectoris or uncontrolled diabetes mellitus).Have central nervous system (CNS) metastases (unless the patient has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before starting study therapy). A screening computed tomography (CT) scan or magnetic resonance imaging (MRI) before enrollment in the absence of a clinical suspicion of brain metastases is not required.
研究者
相似试验
已完成
2 期
A Study of Advanced or Metastatic Non-small Cell Lung CancerNon Small Cell Lung CancerNCT00988858Eli Lilly and Company55
进行中（未招募）
不适用
A Randomized Phase 2 Study of LY2181308 in Combination with Docetaxel versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who Were Previously Treated with First Line Chemotherapy - NDocally advanced or metastaic non-small cell lung cancer, second line therapyMedDRA version: 9.1Level: LLTClassification code 10025054MedDRA version: 9.1Level: LLTClassification code 10025055EUCTR2009-017591-24-ITEli Lilly and Company, Limited180
进行中（未招募）
1 期
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancerocally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 13.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017591-24-GBEli Lilly and Company180
进行中（未招募）
1 期
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancerocally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 14.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017591-24-BEEli Lilly and Company180
进行中（未招募）
不适用
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung CancerEUCTR2009-017591-24-DEEli Lilly and Company180